Jan 11, 2022 / 09:30PM GMT
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst
Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting this fireside chat with Dave Ricks, Chairman and CEO of Eli Lilly. Dave, welcome, and great speaking with you today.
David A. Ricks - Eli Lilly and Company - Chairman, CEO & President
Good to be here.
Questions and Answers:
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior AnalystYes. Last year, we had the big donanemab update, and I think we're hot off the presses on some CMS decision, which we won't spend too much time on today, given the great amount of time to digest that. But would love to just hear some opening remarks just as you think about Lilly's positioning heading into 2022. The company's obviously incredibly well positioned. It's been a big outperformer versus peers. And I would just love to hear how you're thinking about the business as we start the new year.
David A.